MYL9 and inflammatory bowel disease: In the present study, we showed that Myl9/12 molecules are involved in the pathogenesis of IBDs, such as UC and CD, and that the plasma Myl9/12 level depicts the disease severity of IBD, especially in patients with UC, suggesting that the plasma Myl9/12 level may be a useful biomarker for IBD.